Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients.
- Author:
Seung Hoon BEOM
1
;
Dong Wan KIM
;
Sung Hoon SIM
;
Bhumsuk KEAM
;
Jin Hyun PARK
;
Jeong Ok LEE
;
Tae Min KIM
;
Se Hoon LEE
;
Dae Seog HEO
Author Information
- Publication Type:Original Article
- Keywords: Gefitinib; Interstitial lung diseases; Lung injury; Drug-related side effects and adverse reactions; Lung neoplasms
- MeSH: Asian Continental Ancestry Group; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Humans; Incidence; Lung Diseases, Interstitial*; Lung Injury; Lung Neoplasms*; Lung*; Medical Records; Multivariate Analysis; Research Personnel; Retrospective Studies; Seoul; Serum Albumin
- From:Cancer Research and Treatment 2016;48(1):88-97
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Interstitial lung disease (ILD) is a serious adverse effect of gefitinib. We examined the incidence and clinical characteristics of drug-induced ILD in Korean non-small cell lung carcinoma patients treated with gefitinib. MATERIALS AND METHODS: A retrospective cohort study was performed in non-small cell lung cancer (NSCLC) patients who started gefitinib treatment at Seoul National University Hospital from January 2002 through December 2011. Patients who developed new abnormal radiologic findings with respiratory symptoms after gefitinib treatment were defined as having possible adverse pulmonary reactions. The patients' medical records were reviewed independently by investigators to identify the causes of pulmonary toxicities. RESULTS: Among the 1,114 patients evaluated, 128 patients (11.5%) developed pulmonary adverse reactions after taking gefitinib. An infectious complication occurred in 98 patients (8.8%) and 15 patients (1.3%) developed ILD. Nine of the 15 patients (60.0%) with gefitinib-induced ILD experienced a fatal clinical course that met either the Common Terminology Criteria for Adverse Events grade 4 (n=3) or grade 5 (n=6). In the multivariate analysis, a lower serum albumin level (< or = 3.0 g/dL) at baseline was significantly associated with the development of gefitinib-induced ILD (odds ratio, 3.91; 95% confidence interval, 1.20 to 12.71). CONCLUSION: The incidence of gefitinib-induced ILD in Korean NSCLC patients was similar to that reported worldwide, but lower than values reported for Japanese population. ILD was usually a life-threatening adverse effect of gefitinib, and the development of ILD was significantly associated with a lower baseline serum albumin level.
